anti-MUC1 CAR-pNK cells / PersonGen Biomedicine - LARVOL DELTA

Phase I clinical trial with PD-1/MUC1 CAR-pNK92 immunotherapy (CRI-CIMT-EATI-AACR 2018) - "To overcome these barriers, we engineered clinically applicable NK-92 cells by lentiviral gene transfer to express chimeric antigen receptors comprising an anti-MUC1 scFv antibody fusion protein with CD28-CD137 as a signaling moiety and truncated PD-1 peptide. Severe cytokine storm and/or bone marrow suppression were not observed. From this phase I clinical trial we found that CAR-NK therapy has a broad prospect of application as a new cellular immunotherapy due to its stable clinical efficacy, mild side effects and easy to prepare. "

Clinical • IO Biomarker • P1 data • PD(L)-1 Biomarker • Colorectal Cancer • Lung Cancer • Ovarian Cancer • Pancreatic Cancer